Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Veracyte Meets New Medicare Coverage Mandate For Molecular Dx

This article was originally published in The Pink Sheet Daily

Executive Summary

Veracyte announced a positive coverage policy from Palmetto GBA Jan. 9 for its Afirma multi-gene expression classifier test, one of the first to go through the Medicare contractor’s new requirements.

You may also be interested in...



The Balkanized State Of Molecular Diagnostics Reimbursement

Recent moves by CMS have left up in the air an innovative program that gives labs a clearer opportunity to demonstrate clinical utility and test value. It’s therefore unclear whether companies and their backers should expect any greater certainty over the ability to command premium prices for high-value diagnostic tests.

Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls

The Medicare contractor that handles claims for California and several other states is taking steps to enhance its control over reimbursement of molecular diagnostic tests.

With Genetic Test Codes Developed, CMS Undecided On How To Pay For Them

Specific reimbursement codes have been developed for the first time for more than 100 genetic tests, but they will not be adopted by Medicare until at least 2013 as CMS figures out how to incorporate them into the payment system.

Topics

UsernamePublicRestriction

Register

PS073265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel